In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models

Marco Gobbi, Manuela Moia, Marcella Funicello, Antonella Riva, Paolo Morazzoni, Tiziana Mennini

Research output: Contribution to journalArticle

Abstract

Cytokine hypersecretion might be involved in the onset and maintenance of depressive disorders and it has been suggested that St. John's wort extracts (Hypericum perforatum, SJW) might exert their antidepressant-like effects by affecting peripheral interleukin-6 (IL6) expression. We found that hyperforin, one putative active principle of SJW, and its dicyclohexylammonium salt (hyperforin-DCHA), inhibited the substance P (SP)-induced IL6 release in human astrocytoma cells (U373MG) with an IC50 of 1.6 μM, indicating that hyperforin is likely to account for the inhibitory effect previously found in the same experimental model with SJW extracts. [3H]SP binding experiments in parallel on the same intact cells indicate that hyperforin-DCHA does not interact with neurokinin-1 receptors but very likely interacts with some intracellular steps leading to the synthesis and/or release of IL6. Hyperforin-DCHA also inhibited, with a similar IC50, the IL6 release induced in U373MG cells by two other classic proinflammatory stimuli, IL1β and lipopolysaccharide (LPS), as well as the LPS-induced IL6 release in whole rat blood. Hyperforin-DCHA was less active in whole human blood. The concentrations required in vitro to inhibit LPS-induced IL6 release from rat and human whole blood are about one order of magnitude higher than the hyperforin levels measured in the plasma of rats or humans treated with pharmacologically active doses of SJW or hyperforin-DCHA.

Original languageEnglish
Pages (from-to)680-682
Number of pages3
JournalPlanta Medica
Volume70
Issue number7
DOIs
Publication statusPublished - Jul 2004

Fingerprint

hyperforin
interleukin-6
Interleukin-6
Theoretical Models
salts
Hypericum
Lipopolysaccharides
Rats
lipopolysaccharides
Blood
substance P
Substance P
Inhibitory Concentration 50
inhibitory concentration 50
rats
blood
Neurokinin-1 Receptors
hypersecretion
Hypericum perforatum
Astrocytoma

ASJC Scopus subject areas

  • Plant Science
  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. / Gobbi, Marco; Moia, Manuela; Funicello, Marcella; Riva, Antonella; Morazzoni, Paolo; Mennini, Tiziana.

In: Planta Medica, Vol. 70, No. 7, 07.2004, p. 680-682.

Research output: Contribution to journalArticle

Gobbi, Marco ; Moia, Manuela ; Funicello, Marcella ; Riva, Antonella ; Morazzoni, Paolo ; Mennini, Tiziana. / In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. In: Planta Medica. 2004 ; Vol. 70, No. 7. pp. 680-682.
@article{b0f19b09cdc14472906b446c310f92cc,
title = "In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models",
abstract = "Cytokine hypersecretion might be involved in the onset and maintenance of depressive disorders and it has been suggested that St. John's wort extracts (Hypericum perforatum, SJW) might exert their antidepressant-like effects by affecting peripheral interleukin-6 (IL6) expression. We found that hyperforin, one putative active principle of SJW, and its dicyclohexylammonium salt (hyperforin-DCHA), inhibited the substance P (SP)-induced IL6 release in human astrocytoma cells (U373MG) with an IC50 of 1.6 μM, indicating that hyperforin is likely to account for the inhibitory effect previously found in the same experimental model with SJW extracts. [3H]SP binding experiments in parallel on the same intact cells indicate that hyperforin-DCHA does not interact with neurokinin-1 receptors but very likely interacts with some intracellular steps leading to the synthesis and/or release of IL6. Hyperforin-DCHA also inhibited, with a similar IC50, the IL6 release induced in U373MG cells by two other classic proinflammatory stimuli, IL1β and lipopolysaccharide (LPS), as well as the LPS-induced IL6 release in whole rat blood. Hyperforin-DCHA was less active in whole human blood. The concentrations required in vitro to inhibit LPS-induced IL6 release from rat and human whole blood are about one order of magnitude higher than the hyperforin levels measured in the plasma of rats or humans treated with pharmacologically active doses of SJW or hyperforin-DCHA.",
author = "Marco Gobbi and Manuela Moia and Marcella Funicello and Antonella Riva and Paolo Morazzoni and Tiziana Mennini",
year = "2004",
month = "7",
doi = "10.1055/s-2004-827194",
language = "English",
volume = "70",
pages = "680--682",
journal = "Planta Medica",
issn = "0032-0943",
publisher = "Georg Thieme Verlag",
number = "7",

}

TY - JOUR

T1 - In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models

AU - Gobbi, Marco

AU - Moia, Manuela

AU - Funicello, Marcella

AU - Riva, Antonella

AU - Morazzoni, Paolo

AU - Mennini, Tiziana

PY - 2004/7

Y1 - 2004/7

N2 - Cytokine hypersecretion might be involved in the onset and maintenance of depressive disorders and it has been suggested that St. John's wort extracts (Hypericum perforatum, SJW) might exert their antidepressant-like effects by affecting peripheral interleukin-6 (IL6) expression. We found that hyperforin, one putative active principle of SJW, and its dicyclohexylammonium salt (hyperforin-DCHA), inhibited the substance P (SP)-induced IL6 release in human astrocytoma cells (U373MG) with an IC50 of 1.6 μM, indicating that hyperforin is likely to account for the inhibitory effect previously found in the same experimental model with SJW extracts. [3H]SP binding experiments in parallel on the same intact cells indicate that hyperforin-DCHA does not interact with neurokinin-1 receptors but very likely interacts with some intracellular steps leading to the synthesis and/or release of IL6. Hyperforin-DCHA also inhibited, with a similar IC50, the IL6 release induced in U373MG cells by two other classic proinflammatory stimuli, IL1β and lipopolysaccharide (LPS), as well as the LPS-induced IL6 release in whole rat blood. Hyperforin-DCHA was less active in whole human blood. The concentrations required in vitro to inhibit LPS-induced IL6 release from rat and human whole blood are about one order of magnitude higher than the hyperforin levels measured in the plasma of rats or humans treated with pharmacologically active doses of SJW or hyperforin-DCHA.

AB - Cytokine hypersecretion might be involved in the onset and maintenance of depressive disorders and it has been suggested that St. John's wort extracts (Hypericum perforatum, SJW) might exert their antidepressant-like effects by affecting peripheral interleukin-6 (IL6) expression. We found that hyperforin, one putative active principle of SJW, and its dicyclohexylammonium salt (hyperforin-DCHA), inhibited the substance P (SP)-induced IL6 release in human astrocytoma cells (U373MG) with an IC50 of 1.6 μM, indicating that hyperforin is likely to account for the inhibitory effect previously found in the same experimental model with SJW extracts. [3H]SP binding experiments in parallel on the same intact cells indicate that hyperforin-DCHA does not interact with neurokinin-1 receptors but very likely interacts with some intracellular steps leading to the synthesis and/or release of IL6. Hyperforin-DCHA also inhibited, with a similar IC50, the IL6 release induced in U373MG cells by two other classic proinflammatory stimuli, IL1β and lipopolysaccharide (LPS), as well as the LPS-induced IL6 release in whole rat blood. Hyperforin-DCHA was less active in whole human blood. The concentrations required in vitro to inhibit LPS-induced IL6 release from rat and human whole blood are about one order of magnitude higher than the hyperforin levels measured in the plasma of rats or humans treated with pharmacologically active doses of SJW or hyperforin-DCHA.

UR - http://www.scopus.com/inward/record.url?scp=3543013806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543013806&partnerID=8YFLogxK

U2 - 10.1055/s-2004-827194

DO - 10.1055/s-2004-827194

M3 - Article

C2 - 15303261

AN - SCOPUS:3543013806

VL - 70

SP - 680

EP - 682

JO - Planta Medica

JF - Planta Medica

SN - 0032-0943

IS - 7

ER -